Rapid sepsis diagnostic receives funding to boost health innovations in Australia

One of 11 projects selected for $10 million BioMedTech Horizons program investment.

9:30am AEST, Tuesday 17 April, Melbourne, AustraliaMTPConnect – the Medical Technology, Biotechnology, and Pharmaceutical (MTP) Industry Growth Centre – and the Minister for Health, the Hon Greg Hunt MP, today announced that a rapid diagnostic for the pathogens that cause sepsis and 10 other projects are successful recipients of investment from the Australian Government’s $35 million BioMedTech Horizons program. The program aims to help Australia move more cutting edge-ideas and breakthrough discoveries towards proof-of-concept and commercialisation, and stimulate collaboration across disciplines between the research, industry and technology sectors to maximize entrepreneurship and idea potential.

The project, led by Biotech Resources (BTR) is working to develop the world’s first rapid diagnostic test ‘Aimalux’ for the direct detection of the bacteria and fungi that cause sepsis from whole blood. The technology and platform has been developed by the Monash University Centre for Biospectroscopy in Melbourne Australia.

Sepsis is a life-threatening disease that results in the deaths of over 6 million people every year around the world, and more than 5,000 Australians. It is time critical medical emergency. Every hour without treatment increases a patient's chance of dying by 7.6%. And yet there is no definitive test for sepsis with more than 30% of cases going misdiagnosed. If the symptoms of Sepsis are missed and treatment is not administered, then this can result in patient death. This also means that many patients are treated unnecessarily as a precaution, which has its own detrimental consequences as well as adding to the rise of antibiotic resistance super bugs.

Aimalux aims to provide a diagnostic result within 35 minutes, to revolutionize the way sepsis is currently diagnosed, reduce healthcare costs, and save lives.

Peter Jordan, CEO of BTR, said that “BTR is working to ensure that Australia’s world class medical research produced by centres such as the Monash University Centre for Biospectroscopy is commercialised in Australia for the global market. This means working in close partnership with research, clinical, regulatory and product development partners over the many years it takes to develop a new medical diagnostic. This journey would not be possible without the strong support of all levels of government and of the well-established Australian life sciences ecosystem. The BioMedTech Horizons funding is a good example of this. It will allow BTR and our partners to guide our sepsis diagnostic through the clinical trials and product development stages needed to validate the technology allowing it to attract the sizable investment needed to launch medical technology on the global market.”

Sue MacLeman, Managing Director and CEO of MTPConnect, said the BioMedTech Horizons program is providing the necessary support to boost investment, commercialisation and success of health innovations in Australia.

“These first investments from the BioMedTech Horizons program are set to fuel ongoing innovation in Australia, in line with MTPConnect’s priorities for growth of the medical technology, biotechnology and pharmaceutical sector. BTR’s rapid sepsis diagnostic and the other 10 outstanding projects address identified global megatrends including precision healthcare and the digital evolution, as well as forecasted areas of unmet clinical need, such as immunology and advanced prosthetics.”

Minister for Health, the Hon Greg Hunt MP, said, “The Turnbull Government is committed to improving the health services for all Australians and will continue to invest in better treatment, care and medical research.  Our researchers are innovators and this investment will speed up the journey from idea to reality. These technologies have the potential to create better health outcomes for Australians, while driving investment and strengthening our economy. All Australians benefit from investment in health and medical research.”

The BioMedTech Horizons program is being delivered as a part of the Australian Government’s $20 billion Medical Research Future Fund, which aims to transform health and medical research to improve lives, build the economy and contribute to health system sustainability through targeted strategic investment. 

For more information on the BioMedTech Horizons program and first round recipients, please visit: www.mtpconnect.org.au/biomedtechhorizons

About the Project: Rapid diagnostic for the pathogens that cause sepsis

Biotech Resources (BTR), Monash University Centre for Biospectroscopy, The Alfred Hospital,

Monash Health, Hydrix
Biotech Resources (BTR) is working to develop the world’s first rapid diagnostic test ‘Aimalux’ for the direct detection of the bacteria and fungi that cause sepsis from whole blood. The technology and platform has been developed by the Monash University Centre for Biospectroscopy in Melbourne Australia. Sepsis is a life-threatening disease that results in the deaths of over 6 million people every year around the world, and more than 5,000 Australians. It is time critical medical emergency. Every hour without treatment increases a patient's chance of dying by 7.6%. And yet there is no definitive test for sepsis with more than 30% of cases going misdiagnosed. If the symptoms of Sepsis are missed and treatment is not administered, then this can result in patient death. This also means that many patients are treated unnecessarily as a precaution, which has its own detrimental consequences as well as adding to the rise of antibiotic resistance super bugs. Aimalux aims to provide a diagnostic result within 35 minutes, to revolutionise the way sepsis is currently diagnosed, reduce healthcare costs, and save lives.

 About Biotech Resources (BTR)

Biotech Resources (BTR) is commercialising a new point of care platform for diagnosing disease. Our mission is to provide access to rapid and accurate disease diagnosis to reduce mortality and morbidity globally while lowering the cost of health care worldwide. The technology and platform has been developed by the Monash University Centre for Biospectroscopy.

www.btrdiagnostic.com

About the Monash Centre for Biospectroscopy

www.monash.edu/science/cfb

About Hydrix

Hydrix specialises in the design and development of high technology devices for a wide range of industries for Clients around the world. We offer a comprehensive range of software and electronic product design services ranging from applied research and initial concept definition and specification, through all stages of engineering, development, prototyping, manufacturer management and certification process management for global markets. Hydrix is about "Excellence in Engineering"

www.hydrix.com

About MTPConnect

MTPConnect was formed as a not-for-profit organisation in November 2015 as part of the Australian Government’s Industry Growth Centres Initiative to accelerate the rate of growth of the MTP sector to achieve greater commercialisation and establish Australia as an Asia-Pacific hub for MTP companies.

The MTPConnect Head Office is located at the New Horizons Building at Monash University, co-located with CSIRO and industry. There are also key hubs at the University of Sydney’s Institute of Biomedical Engineering and Technology and the Medical Device Research Institute at Flinders University at Tonsley in Adelaide.

Industry Growth Centres

The Industry Growth Centres Initiative is an industry-led approach driving innovation, productivity and competitiveness by focusing on areas of competitive strength and strategic priority. This will help Australia transition into smart, high value and export focused industries.

The Initiative enables national action on key issues such as collaboration, commercialisation, international engagement, skills and regulation reform. It drives excellence, not dependence, and will create an economy that ensures Australia’s ongoing prosperity. For more information: www.industry.gov.au/industrygrowthcentres


Media inquiries

Rapid sepsis diagnostic
Peter Jordan
CEO Biotech Resources (Aust) Pty. Ltd.
+61 404 878 213
peter.jordan@btrdiagnostics.com

MTP Connect
Zoe Stephenson   
Corporate Communications Manager  
+61 417 267 739
zoe.stephenson@mtpconnect.org.au